533 related articles for article (PubMed ID: 12791825)
1. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
3. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
5. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
Liepe K; Geidel HH; Bergmann R; Haase M; Runge R; Kotzerke J
Nucl Med Commun; 2009 Sep; 30(9):693-9. PubMed ID: 19528873
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
Pirayesh E; Amoui M; Mirzaee HR; Tabei F; Rakhsha A; Kalantari BA; Shafiei B; Assadi M; Asli IN
J Nucl Med Technol; 2013 Sep; 41(3):192-6. PubMed ID: 23918612
[TBL] [Abstract][Full Text] [Related]
7. Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
van Aswegen A; Roodt A; Marais J; Botha JM; Naudé H; Lötter MG; Goedhals L; Doman MJ; Otto AC
Nucl Med Commun; 1997 Jun; 18(6):582-8. PubMed ID: 9259533
[TBL] [Abstract][Full Text] [Related]
8. Re-186 HEDP conditioning therapy in patients with advanced acute lymphoblastic leukemia before allogeneic bone marrow transplantation.
Döbert N; Martin H; Kranert WT; Menzel C; Klein SA; Mose S; Grünwald F
Clin Nucl Med; 2003 Sep; 28(9):738-42. PubMed ID: 12972995
[TBL] [Abstract][Full Text] [Related]
9. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
Graham MC; Scher HI; Liu GB; Yeh SD; Curley T; Daghighian F; Goldsmith SJ; Larson SM
Clin Cancer Res; 1999 Jun; 5(6):1307-18. PubMed ID: 10389913
[TBL] [Abstract][Full Text] [Related]
10. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
[TBL] [Abstract][Full Text] [Related]
11. Systemic radionuclide therapy in pain palliation.
Liepe K; Runge R; Kotzerke J
Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
[TBL] [Abstract][Full Text] [Related]
12. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
13. Radiation dose estimates in humans for (11)C-acetate whole-body PET.
Seltzer MA; Jahan SA; Sparks R; Stout DB; Satyamurthy N; Dahlbom M; Phelps ME; Barrio JR
J Nucl Med; 2004 Jul; 45(7):1233-6. PubMed ID: 15235071
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
15. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
de Klerk JM; van Dijk A; van het Schip AD; Zonnenberg BA; van Rijk PP
J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
[TBL] [Abstract][Full Text] [Related]
17. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.
Kemerink GJ; Liu X; Kieffer D; Ceyssens S; Mortelmans L; Verbruggen AM; Steinmetz ND; Vanderheyden JL; Green AM; Verbeke K
J Nucl Med; 2003 Jun; 44(6):947-52. PubMed ID: 12791824
[TBL] [Abstract][Full Text] [Related]
18. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma.
Syed R; Bomanji J; Nagabhushan N; Kayani I; Groves A; Waddington W; Cassoni A; Ell PJ
J Nucl Med; 2006 Dec; 47(12):1927-35. PubMed ID: 17138735
[TBL] [Abstract][Full Text] [Related]
19. Rhenium-188-HEDP in the palliative treatment of bone metastases.
Liepe K; Hliscs R; Kropp J; Grüning T; Runge R; Koch R; Knapp FF; Franke WG
Cancer Biother Radiopharm; 2000 Jun; 15(3):261-5. PubMed ID: 10941533
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Stokkel MP; Han SH; Blijham GH; van Rijk PP
J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
